Monday, June 22, 2026

Humans may have hidden regenerative powers

 

For generations, scientists have viewed the inability to regrow lost body parts as one of the fundamental limitations of humans and other mammals. While creatures such as salamanders can regenerate entire limbs, humans typically heal injuries by forming scar tissue.

New research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS), however, suggests that regenerative abilities may not be entirely absent in mammals. Instead, they could be hidden within the body's normal healing machinery, waiting to be activated under the right conditions.

"Why some animals can regenerate and others, particularly humans, can't is a big question that has been asked since Aristotle," said Dr. Ken Muneoka, a professor in the VMBS' Department of Veterinary Physiology & Pharmacology (VTPP). "I've spent my career trying to understand that."

In a study published in Nature Communications, Muneoka and colleagues describe a new two-step treatment that enabled the regeneration of bone, joint structures, and ligaments. Although the regrown tissues were not perfect replicas of the originals, the researchers believe the approach could eventually help reduce scarring and improve tissue repair after amputations.

Redirecting Healing Away From Scar Formation

When mammals are injured, the body usually responds with fibrosis. During this process, fibroblast cells quickly close the wound and create scar tissue. While this response helps prevent infection and further damage, it also limits the body's ability to rebuild what was lost.

Animals capable of regeneration follow a different path. In salamanders, for example, similar cells gather into a structure called a blastema, which serves as a foundation for new tissue growth.

"It's as if these cells can move in two different directions," Muneoka said. "They could either make a scar or make a blastema. Our research focused on redirecting the behavior of fibroblasts already present at the injury site."

To explore whether mammalian healing could be pushed toward regeneration, the research team developed a treatment that uses two well-known growth factors in sequence.

The first step involved applying fibroblast growth factor 2 (FGF2) after the wound had already healed over. By waiting until the initial healing process was complete, the researchers allowed the body to respond normally before intervening.

According to Muneoka, the team then "changed what happens next."

FGF2 encouraged the formation of a blastema-like structure, something that does not typically occur in mammals after this type of injury. Several days later, the researchers applied a second growth factor, bone morphogenetic protein 2 (BMP2), which prompted those cells to begin building new tissues.

"This is really a two-step process," Muneoka said. "You first shift the cells away from scarring, and then you provide the signals that tell them what to build."

Rethinking the Role of Stem Cells

One of the study's most important findings is that regeneration may not require adding stem cells from outside the body, an approach commonly explored in regenerative medicine.

"You don't have to actually get stem cells and put them back in," Muneoka said. "They're already there -- you just need to learn how to get them to behave the way you want."

Dr. Larry Suva, another VTPP professor involved in the study, said the results challenge long-standing assumptions about what mammalian cells are capable of doing.

"The cells that we thought to be unprogrammable, in fact are," Suva said. "The capacity is not absent -- it's just obscured."

The researchers also found evidence that cells can be redirected to create structures outside their usual location. This process, known as positional re-specification, is an important part of development.

In practical terms, cells that would normally help form one type of tissue can be instructed to rebuild a different structure following an injury.

Regrowing Bone, Tendons, Ligaments, and Joints

Although the regenerated tissues were not exact matches to the original anatomy, the researchers successfully restored all of the major structures that had been removed during amputation, including bone, tendon, ligament, and joint tissue.

The regenerated areas contained both skeletal components and connective tissues arranged in patterns resembling natural anatomy.

"We regenerated what you would expect to see at that level of injury," Muneoka said. "The structures are there -- just not in a perfect form."

The findings also suggest that regeneration depends on multiple biological pathways working together. Rebuilding tissue appears to be far more complex than activating a single mechanism.

Potential Benefits for Wound Healing

While the research remains in its early stages, the scientists believe it could have practical applications long before complete regeneration becomes possible.

Rather than focusing solely on replacing missing structures, the approach may help improve healing outcomes by reducing scar formation and enhancing tissue repair.

"People should start thinking about using these signals during the healing process," Muneoka said. "Even shifting the response slightly away from scarring could have real benefits."

The path toward clinical testing may also be more straightforward than with many experimental therapies. BMP2 already has FDA approval for certain medical applications, and FGF2 is currently being evaluated in multiple clinical trials.

A New View of Mammalian Regeneration

The study adds to growing evidence that regeneration in mammals may not be a completely lost trait. Instead, it may be a dormant capability that normally remains inactive during healing.

"This changes the way we think about what's possible," Suva said. "Once you show that regeneration can be activated, it opens the door to asking entirely new questions."

For Muneoka, those questions have driven decades of research and now have a promising new framework.

"Regenerative failure in mammals can be rescued," he said. "Now we have a model to begin figuring out how."

Journal Reference:

  1. Ling Yu, Mingquan Yan, Katherine Zimmel Scaturro, Osama Qureshi, Yu-Lieh Lin, Benjamin B. Bartelle, C. Addison Smith, Daniel Osorio Hurtado, James J. Cai, Lindsay A. Dawson, Regina Brunauer, Larry J. Suva, Manjong Han, Connor P. Dolan, Ken Muneoka. Digit regeneration in mice is stimulated by sequential treatment with FGF2 and BMP2. Nature Communications, 2026; 17 (1) DOI: 10.1038/s41467-026-72066-8

Courtesy:

Texas A&M University. "Humans may have hidden regenerative powers." ScienceDaily. ScienceDaily, 17 June 2026. <www.sciencedaily.com/releases/2026/06/260617032207.htm>.

Sunday, June 21, 2026

Scientists reprogram brain immune cells to fight Alzheimer’s


Researchers in Spain and Switzerland have identified an experimental molecule that may help restore the brain's natural defenses against Alzheimer's disease. The compound, known as OLE, appears to "reprogram" microglia, the brain's immune cells, allowing them to regain some of their protective abilities.

The research was led by José Vicente Sánchez Mut of the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and Miguel Hernández University of Elche (UMH), together with Johannes Gräff of the École Polytechnique Fédérale de Lausanne (EPFL). Their findings were published in the journal Cell Death and Disease.

According to the study, OLE helps microglia surround and contain beta-amyloid plaques, reducing both their size and their harmful effects. In animal studies, the treatment also led to better performance on memory tests.

How OLE Targets Alzheimer's Disease

One of the hallmarks of Alzheimer's disease is the buildup of beta-amyloid plaques in the brain. At the same time, microglia, which normally help remove these toxic deposits, gradually become less effective. As their protective functions decline, they can contribute to damage in brain cells.

The researchers found that OLE, a molecule derived from the PM20D1 gene, can shift microglia back into a more protective state. After treatment, the cells moved toward beta-amyloid plaques and surrounded them, creating a barrier that limited contact between the plaques and nearby neurons. This reduced the plaques' toxic impact on brain tissue.

"One of the most significant findings is that we have identified a molecule capable of restoring microglia's protective function," explains Sánchez Mut. "In Alzheimer's disease, these cells become progressively impaired. Our results suggest that this process can be reversed, pointing to new therapeutic and research avenues to counteract the disease," adds the researcher, who leads the Functional Epi-Genomics of Aging and Alzheimer's Disease laboratory at the IN CSIC-UMH.

Testing OLE in Worms and Mice

To evaluate the effects of OLE, the researchers used several experimental models.

The first involved genetically modified worms (C. elegans) that produce beta-amyloid. Because these worms develop disease-related damage quickly, they provide a useful way to study toxicity. Treatment with OLE reduced the buildup of protein aggregates and improved the animals' movement, indicating a protective effect.

The team then tested the compound in mouse models of Alzheimer's disease. Mice received OLE for three months, after which researchers examined both memory and brain changes. The treated animals performed better on memory tests and showed fewer beta-amyloid plaques than untreated mice.

Microglia Show the Strongest Response

To better understand how OLE works, the researchers examined the activity of thousands of individual cells in the brain. Their analysis revealed that microglia were the cells most strongly affected by the treatment.

Following exposure to OLE, microglia activated pathways involved in clearing beta-amyloid and regained their ability to move toward plaques and contain them.

"Single-cell analysis allowed us to determine that microglia were the cells that responded most strongly to the treatment," says Victoria Pozzi, first author of the study. "From there, we observed that the compound helped these cells move toward beta-amyloid plaques and better contain the damage associated with the disease," adds the researcher.

Additional experiments in cell cultures produced similar results. Microglia treated with OLE were more effective at moving toward beta-amyloid deposits and helping remove them. In separate neuronal cultures exposed to conditions resembling those seen in Alzheimer's disease, OLE improved cell survival, suggesting the compound may also directly protect neurons.

Potential for Future Alzheimer's Therapies

The findings are covered by two European patents, including one owned by the CSIC. The researchers say this strengthens the translational potential of the work and supports future efforts to develop therapeutic applications based on the discovery.

The study received funding from the Dementia Research Switzerland -- Synapsis Foundation (Switzerland), the Pasqual Maragall Researchers Programme (PMRP) of the Pasqual Maragall Foundation, the Spanish Ministry of Science, Innovation and Universities, the Severo Ochoa Centres of Excellence programme of the State Research Agency (AEI), the Prometeo program of the Generalitat Valenciana, the European Regional Development Fund (ERDF), and the CSIC Interdisciplinary Thematic Platform PTI+ NEURO-AGING. Additional support came from the Swiss National Science Foundation, the École Polytechnique Fédérale de Lausanne (EPFL), the European Research Council (ERC), the National Research Foundation of Korea (NRF), and the European Social Fund (ESF+).

Journal Reference:

  1. Victoria Pozzi-Ruiz, Aida Giner de Gracia, Liliane Glauser, Mario Romani, Fatima Gunter-Rahman, Alejandro González-Ramón, Mahmood Haj-Yahya, Rajasekhar Kolla, Allison M. Burns, Hilal A. Lashuel, Johan Auwerx, Johannes Gräff, Jose V. Sanchez-Mut. The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease. Cell Death, 2026; 17 (1) DOI: 10.1038/s41419-026-08791-1

Courtesy:

Universidad Miguel Hernandez de Elche. "Scientists reprogram brain immune cells to fight Alzheimer’s." ScienceDaily. ScienceDaily, 19 June 2026. <www.sciencedaily.com/releases/2026/06/260619020506.htm>.